CIK 0001023024 · Large accelerated filer
ANI PHARMACEUTICALS INC
Sign in to watch- Ticker
- ANIP
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 582301143
- Phone
- 6097591810
- Business address
- 104 CARNEGIE CENTER DRIVE SUITE 300, PRINCETON, NJ, 08540
- Former names
- BIOSANTE PHARMACEUTICALS INC, BEN ABRAHAM TECHNOLOGIES INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $1,939,756
- in 9 filings, $1.9M under 10b5-1 plans
Net −$1,939,756. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-03-23 | Marken James G. SVP OPS & PROD DEV | Shares withheld for taxes | −3,653 | $69.58 | $254K | 118,805 |
| 2024-03-13 | Cook Meredith SR. VP, GENERAL COUNSEL & SEC. | Sale 10b5-1 | −250 | $66.54 | $17K | 59,981 |
| 2024-03-11 | Gassert Chad SVP - CORP. DEV. & STRATEGY | Sale 10b5-1 | −20,000 | $65.81 | $1.3M | 273,226 |
| 2024-03-11 | CAREY STEPHEN P. SVP & CFO | Sale | −7,787 | $65.55 | $510K | 177,712 |
| 2024-03-08 | Shanmugam Muthusamy HEAD OF R&D, COO-NOVITIUM OPS | Sale 10b5-1 | −10,000 | $67.17 | $672K | 832,620 |
| 2024-03-08 | Lalwani Nikhil PRESIDENT & CEO | Sale | −16,292 | $67.13 | $1.1M | 411,629 |
| 2024-03-07 | CAREY STEPHEN P. SVP & CFO | Shares withheld for taxes | −4,216 | $66.71 | $281K | 185,499 |
| 2024-03-07 | Lalwani Nikhil PRESIDENT & CEO | Shares withheld for taxes | −17,060 | $66.71 | $1.1M | 427,921 |
| 2024-03-07 | Shanmugam Muthusamy HEAD OF R&D, COO-NOVITIUM OPS | Sale 10b5-1 | −15,085 | $66.35 | $1.0M | 842,620 |
| 2024-03-07 | Mutz Christopher HEAD OF RARE DISEASE | Shares withheld for taxes | −2,110 | $66.71 | $141K | 85,277 |
| 2024-03-07 | Gutwerg Ori SVP, GENERICS | Shares withheld for taxes | −2,494 | $66.71 | $166K | 80,212 |
| 2024-03-07 | Marken James G. SVP OPS & PROD DEV | Sale | −24,338 | $66.37 | $1.6M | 124,492 |
| 2024-03-07 | Marken James G. SVP OPS & PROD DEV | Shares withheld for taxes | −2,034 | $66.71 | $136K | 122,458 |
| 2024-03-06 | Lalwani Nikhil PRESIDENT & CEO | Sale | −28,965 | $65.52 | $1.9M | 444,981 |
| 2024-03-06 | Shanmugam Muthusamy HEAD OF R&D, COO-NOVITIUM OPS | Sale 10b5-1 | −14,822 | $65.47 | $970K | 857,705 |
| 2024-03-05 | Shanmugam Muthusamy HEAD OF R&D, COO-NOVITIUM OPS | Sale 10b5-1 | −10,093 | $65.35 | $660K | 872,527 |
| 2024-03-05 | Mutz Christopher HEAD OF RARE DISEASE | Sale | −5,000 | $66.00 | $330K | 87,387 |
| 2024-03-04 | Pera Antonio R Director | Sale | −7,000 | $65.20 | $456K | 26,627 |
| 2024-02-29 | Davis Krista SVP, CHIEF HR OFFICER | Shares withheld for taxes | −1,173 | $67.67 | $79K | 51,545 |
| 2024-02-29 | Cook Meredith SR. VP, GENERAL COUNSEL & SEC. | Shares withheld for taxes | −1,173 | $67.67 | $79K | 60,231 |
Page 14 of 23 · 442 trades